We are developing a broad-spectrum antiviral to prevent and treat infectious diseases, with a focus on diseases such as Dengue, which have a large impact on global health. Our products will be oral and non-refrigerated, so they will be affordable by people in low- and middle income countries. Our antiviral can have applications in other human and veterinary diseases, so part of the business is based on licenses. We prioritize impact investors.